Brief: Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil
17/03/2026 11:41
March 17 (Reuters) - Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS ANNOUNCES APPROVAL OF ADDITIONAL INDICATION FOR MINJUVI® (TAFASITAMAB) IN BRAZIL Source text: ID:nGNX2DMdWK Further company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Incyte
See all newsIncyte Corp reports results for the quarter ended September 30 - Earnings Summary
Incyte Q3 adjusted loss per share beats estimates
Revolution Medicines falls after Incyte posts competitive pancreatic cancer data
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US RESEARCH ROUNDUP-Eli Lilly, Netflix, Zscaler